Grail's Stock Surges After FDA Advisory Committee Endorses Multi-Cancer Early Detection Test
Grail (NASDAQ: GRAL) has seen its stock rise by over 180% in six months, driven largely by a favorable vote from an FDA advisory committee on the safety and effectiveness of its multi-cancer early detection test, Galleri. This marks a significant turnaround for Grail following a February decline due to disappointing trial results. The approval is seen as a critical step toward broader adoption of Galleri, particularly if medical insurers decide to cover it. While FDA pre-market approval may follow the advisory vote, convincing insurers that the test is both effective and cost-efficient remains key. Early detection through Galleri could reduce late-stage cancer diagnoses and lower long-term treatment costs. Data from two major studies shows promising results for detecting 12 deadly cancers with high sensitivity rates and positive predictive values. If these findings are compelling enough, widespread adoption of the test is possible.
Tickers: $GRAL
Topics: biotech insurance_coverage medical_devices stock_movement